Typhoid fever is a serious systemic infection caused by the enteric pathogen Salmonella enterica serovar typhi. S typhi is spread by the fecal-oral route. Although largely an endemic disease, S. typhi has epidemic potential. This research aims to determine the long-term immune response after administration of one dose of Bio TCV and PQed TCV vaccines in the population in Indonesia. Research participants will be taken from research participants who complete the Bio TCV (Typhoid 0319) Phase III clinical trial research included in the Main Study Group I.
Healthy
Subject/Parents/legal guardian(s) have been informed properly regarding the study and signed the informed consent form/and informed assent form.
Subject/parents/legal guardian(s) will commit to comply with the instructions of the investigator and the schedule of the trial.
History of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy.
Subjects who previously enrolled in Phase 3 study Typhoid 0319 in Main Study I
Cohort
Prospective
Not listed
To evaluate antibody persistence 5 years after vaccination with one dose of Vi-DT vaccine (Bio TCV), compared to PQed TCV (Typbar)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
